CRDF
CRDF
NASDAQ · Biotechnology

Cardiff Oncology Inc

$1.30
+0.03 (+2.36%)
As of Jun 30, 10:32 PM ET ·
Financial Highlights (FY 2026)
Revenue
610.9K
Net Income
-47,087,867
Gross Margin
100.0%
Profit Margin
-7,732.0%
Rev Growth
+15.0%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 100.0% 100.0% 56.1% 56.1%
Operating Margin -8,256.3% -7,430.7% -18.4% -15.5%
Profit Margin -7,732.0% -7,345.4% -21.6% -17.5%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 610.9K 531.3K 16.05M 19.98M
Gross Profit 610.9K 531.3K 9.01M 11.22M
Operating Income -50,438,354 -39,476,927 -2,950,777 -3,087,601
Net Income -47,087,867 -36,854,578 -3,462,613 -3,502,482
Gross Margin 100.0% 100.0% 56.1% 56.1%
Operating Margin -8,256.3% -7,430.7% -18.4% -15.5%
Profit Margin -7,732.0% -7,345.4% -21.6% -17.5%
Rev Growth +15.0% +15.0% +0.8% +4.1%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 38.47M 47.77M
Total Equity 57.67M 59.42M
D/E Ratio 0.67 0.80
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -49,902,157 -41,227,105 -3,307,317 -3,822,507
Free Cash Flow -2,137,974 -3,204,130